Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may pose heightened risks for kidney, pancreatic, and gastrointestinal problems. While effective in appetite and addiction control,

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

"All these years I thought that thin people -- those people -- just had more willpower," Winfrey said on her podcast.

In a discussion with Oprah, Dr Ania called obesity a disease. She also advised that we should treat obesity like other medical conditions.

Oprah Winfrey shared that weight-loss medications like Ozempic and Wegovy helped her understand the challenges of being thin. After losing nearly 50 pounds, she emphasized that these drugs assist in managing cravings and support a healthier lifestyle amidst her struggles with weight.